Solid Biosciences Inc.
Financials
Valuation Metrics
Solid Biosciences Inc.'s Market Cap is $954M. At end of 2025 it was $534M. Ranked #2496 of 3,121 in US market (top 80%), #1032 of 1,463 on NASDAQ (top 71%), #192 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 72%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $954M | US#2,496/3,121 Sec#192/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-207M | US—/3,121 Sec—/266 |
| Total Assets | $421M | US#2,827/3,121 Sec#181/266 |
| Net Assets | $374M | US#2,416/3,121 Sec#142/266 |
| Employees | 121 | US#2,593/3,121 Sec#165/266 |
| Value | ||
| P/B | 2.55x | US#1,558/3,121 Sec#72/266 |
| FCF Yield | -19.68% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -55.36% | US#2,703/3,121 Sec#165/266 |
| ROA | -49.24% | US#2,987/3,121 Sec#212/266 |
| Financial Health | ||
| Debt Ratio | 12.43% | US#141/3,121 Sec#59/266 |
| Total Debt | $20M | US#2,758/3,121 Sec#190/266 |
| FCF | $-188M | US#2,767/3,121 Sec#202/266 |
| Cash | $159M | US#1,918/3,121 Sec#130/266 |
| Current Ratio | 13.82x | US#185/3,121 Sec#56/266 |
| Performance | ||
| 1Y Return | 63.60% | US#424/3,121 Sec#89/266 |
| 1M Return | -8.62% | US#1,267/3,121 Sec#117/266 |
| From 52W High | -22.27% | US#1,659/3,121 Sec#125/266 |
| 1Y MDD | -38.59% | US#1,946/3,121 Sec#133/266 |
| Trading | ||
| Volume | 3,065,633 shares | US#1,250/3,121 Sec#133/266 |
| Trading Value | $27M | US#2,324/3,121 Sec#190/266 |
| Per Share | ||
| EPS | $-1.93 | US—/3,121 Sec—/266 |
| BPS | $3.49 | US#2,424/3,121 Sec#154/266 |
Company Info
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.